ROS1 and inflammatory myofibroblastic tumor: Crizotinib, a tyrosine kinase inhibitor targeting ALK, MET, ROS1, and RON, is recommended by the National Comprehensive Cancer Network (NCCN) as a treatment option for ALK-positive IMT (Von Mehren et al., 2022; Trahair et al., 2019; Hunt et al., 2023).